Vignot Stéphane, Soria Jean-Charles
Inserm U981, Institut Gustave-Roussy, 114, rue Édouard-Vaillant, 94805 Villejuif Cedex, France.
Bull Cancer. 2013 Jun;100(6):561-8. doi: 10.1684/bdc.2013.1767.
Molecular characterization of tumors is critical for the development and appropriate use of many anti-cancer agents. Potential discrepancies between primary tumor and secondary lesions lead to question on the optimal modalities for evaluation of biomarkers. In light of recent data, the need of iterative biopsies in metastatic setting has been suggested but technical and methodological limits in such analyses should not be ignored and this strategy can not be definitively validated. The evaluation of spatial and temporal variability of biomarkers in solid tumors should take into account tumoral context and therapeutic history of each patient for the development of personalized medicine in oncology.
肿瘤的分子特征对于许多抗癌药物的研发和合理使用至关重要。原发性肿瘤与继发性病变之间可能存在的差异引发了关于生物标志物评估最佳方式的疑问。鉴于近期的数据，有人提出在转移情况下需要进行反复活检，但此类分析中的技术和方法限制不容忽视，且这一策略无法得到最终验证。在实体瘤中评估生物标志物的时空变异性时，应考虑每位患者的肿瘤背景和治疗史，以推动肿瘤学个性化医疗的发展。
